Pathogenesis of Chronic Lymphocytic Leukemia and the Development of Novel Therapeutic Strategies

Overview

Journal J Clin Exp Hematop

Specialties Hematology
Pathology

Date 2020 Nov 5

PMID 33148933

Citations 17

Authors

Yoshikane Kikushige

Affiliations

Soon will be listed here.

Abstract

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western countries and is characterized by the clonal expansion of mature CD5 B cells. There have been substantial advances in the field of CLL research in the last decade, including the identification of recurrent mutations, and clarification of clonal architectures, signaling molecules, and the multistep leukemogenic process, providing a comprehensive understanding of CLL pathogenesis. Furthermore, the development of therapeutic approaches, especially that of molecular target therapies against CLL, has markedly improved the standard of care for CLL. This review focuses on the recent insights made in CLL leukemogenesis and the development of novel therapeutic strategies.

Citing Articles

Real world outcomes with Ibrutinib monotherapy in chronic lymphocytic leukemia: a single center experience.

Mesaros O, Jimbu L, Rus I, Parvu A, Tomuleasa C, Dima D Med Pharm Rep. 2025; 98(1):36-45.

PMID: 39949913 PMC: 11817578. DOI: 10.15386/mpr-2800.

Insights into genetic aberrations and signalling pathway interactions in chronic lymphocytic leukemia: from pathogenesis to treatment strategies.

Sobczynska-Konefal A, Jasek M, Karabon L, Jaskula E Biomark Res. 2024; 12(1):162.

PMID: 39732734 PMC: 11682641. DOI: 10.1186/s40364-024-00710-w.

Collision tumor comprised of chronic lymphocytic leukemia and myxopapillary ependymoma.

Aly A, Nagaraju S, Price R Surg Neurol Int. 2024; 15:282.

PMID: 39246779 PMC: 11380831. DOI: 10.25259/SNI_658_2023.

Causal Relationship Between Gut Microbiota and Leukemia: Future Perspectives.

Yang Q, Wang Z, Liu M, Gan L Oncol Ther. 2024; 12(4):663-683.

PMID: 39217582 PMC: 11573970. DOI: 10.1007/s40487-024-00300-8.

GLP and G9a histone methyltransferases as potential therapeutic targets for lymphoid neoplasms.

Silva-Carvalho A, Filiu-Braga L, Bogea G, de Assis A, Pittella-Silva F, Saldanha-Araujo F Cancer Cell Int. 2024; 24(1):243.

PMID: 38997742 PMC: 11249034. DOI: 10.1186/s12935-024-03441-y.

References

Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T . The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell. 2010; 17(1):28-40. DOI: 10.1016/j.ccr.2009.11.019. View

Caligaris-Cappio F . Role of the microenvironment in chronic lymphocytic leukaemia. Br J Haematol. 2003; 123(3):380-8. DOI: 10.1046/j.1365-2141.2003.04679.x. View

Lanasa M, Allgood S, Volkheimer A, Gockerman J, Whitesides J, Goodman B . Single-cell analysis reveals oligoclonality among 'low-count' monoclonal B-cell lymphocytosis. Leukemia. 2009; 24(1):133-40. PMC: 2806490. DOI: 10.1038/leu.2009.192. View

Chung S, Kim E, Park J, Chung Y, Lito P, Teruya-Feldstein J . Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Sci Transl Med. 2014; 6(238):238ra71. PMC: 4501573. DOI: 10.1126/scitranslmed.3008004. View

Riches J, Davies J, McClanahan F, Fatah R, Iqbal S, Agrawal S . T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2012; 121(9):1612-21. PMC: 3587324. DOI: 10.1182/blood-2012-09-457531. View

Minden M, Ubelhart R, Schneider D, Wossning T, Bach M, Buchner M . Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature. 2012; 489(7415):309-12. DOI: 10.1038/nature11309. View

Cimmino A, Calin G, Fabbri M, Iorio M, Ferracin M, Shimizu M . miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005; 102(39):13944-9. PMC: 1236577. DOI: 10.1073/pnas.0506654102. View

Hoogeboom R, van Kessel K, Hochstenbach F, Wormhoudt T, Reinten R, Wagner K . A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi. J Exp Med. 2013; 210(1):59-70. PMC: 3549718. DOI: 10.1084/jem.20121801. View

Hallek M, Fischer K, Fingerle-Rowson G, Fink A, Busch R, Mayer J . Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010; 376(9747):1164-74. DOI: 10.1016/S0140-6736(10)61381-5. View

10.

Robak T, Warzocha K, Govind Babu K, Kulyaba Y, Kuliczkowski K, Abdulkadyrov K . Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. Leuk Lymphoma. 2016; 58(5):1084-1093. DOI: 10.1080/10428194.2016.1233536. View

11.

Roberts A, Davids M, Pagel J, Kahl B, Puvvada S, Gerecitano J . Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2015; 374(4):311-22. PMC: 7107002. DOI: 10.1056/NEJMoa1513257. View

12.

Chiorazzi N, Rai K, Ferrarini M . Chronic lymphocytic leukemia. N Engl J Med. 2005; 352(8):804-15. DOI: 10.1056/NEJMra041720. View

13.

Caligaris-Cappio F, Bertilaccio M, Scielzo C . How the microenvironment wires the natural history of chronic lymphocytic leukemia. Semin Cancer Biol. 2013; 24:43-8. DOI: 10.1016/j.semcancer.2013.06.010. View

14.

Hoellenriegel J, Meadows S, Sivina M, Wierda W, Kantarjian H, Keating M . The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011; 118(13):3603-12. PMC: 4916562. DOI: 10.1182/blood-2011-05-352492. View

15.

Lad D, Varma S, Varma N, Sachdeva M, Bose P, Malhotra P . Regulatory T-cell and T-helper 17 balance in chronic lymphocytic leukemia progression and autoimmune cytopenias. Leuk Lymphoma. 2014; 56(8):2424-8. DOI: 10.3109/10428194.2014.986479. View

16.

Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B . The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2010; 117(2):563-74. PMC: 3031480. DOI: 10.1182/blood-2010-05-284984. View

17.

Rawstron A, Bennett F, OConnor S, Kwok M, Fenton J, Plummer M . Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med. 2008; 359(6):575-83. DOI: 10.1056/NEJMoa075290. View

18.

Kalachikov S, Migliazza A, Cayanis E, Fracchiolla N, Bonaldo M, Lawton L . Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia. Genomics. 1997; 42(3):369-77. DOI: 10.1006/geno.1997.4747. View

19.

Ahn I, Underbayev C, Albitar A, Herman S, Tian X, Maric I . Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood. 2017; 129(11):1469-1479. PMC: 5356450. DOI: 10.1182/blood-2016-06-719294. View

20.

Ghosh A, Secreto C, Boysen J, Sassoon T, Shanafelt T, Mukhopadhyay D . The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. Blood. 2010; 117(6):1928-37. PMC: 3056640. DOI: 10.1182/blood-2010-09-305649. View